• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Blog
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    Medical
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training
Pharmintel

Preclinical Rheumatoid Arthritis: Pipeline Analysis & Biomarker Insight, H1 2018.

Scope of report

  • The report provides brief overview of Preclinical RA.
  • This report discusses ‘risk factors for development of RA’ and ‘at risk population’.
  • This report provides comparison of ‘at risk population’ and ‘classified RA patients’ based on biomarker analysis.
  • This report discusses lessons learned from animal studies
  • This report elaborates biomarker insight from retrospective human studies
  • The report covers clinical therapeutics in development for preclinical RA including product profiles, trial summaries.
  • The report mentions rational of clinical trial designs and insight from clinical trials.
  • The report elaborates Potential methodologies for investigating preclinical RA.
  • The report features clinical Pipeline insight based on MOA, sponsor & route of administration
  • The report also covers preclinical pipeline insight.
  • The report captures recent news and collaborations in development of therapeutics for preclinical RA

Reasons to buy

  • The report provides brief overview of Preclinical RA.
  • The report provides a snapshot of the global therapeutic landscape of Preclinical RA.
  • The report assesses Preclinical RA pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA) and route of administration (RoA).
  • The report reviews Preclinical RA pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development for Preclinical RA ranging from discovery to pre-registration and undisclosed stages.
  • The report features descriptive drug profiles for the pipeline products which includes, product briefs, MoA description, rationale of development, clinical trial details with results if published, partnerships activity & current status.

Companies covered

Bristol-Myers Squibb, Johnson & Johnson, Padlock Therapeutics, Cell Therapeutics, ModiQuest Research,

Key Drugs

Abatacept, Hydroxychloroquine, Rituximab, Methotrexate, Atorvastatin

Publisher: Pharmintel

Format: Microsoft word/PDF

Pages: 47

Price:

  • Single Use: $1000
  • Site License: $1500
  • Global License: $2000

Report Inquiry





Leave a Reply

Your email address will not be published.

Contact
+91 9643310025, 9643312749
© 2019 Pharmintel